IMNM

Analyst Note: Immunome, Inc. (IMNM)

Date: 2026-06-13 Current Price: $18.74

1. Structural Readiness

• State: Context-Only (No structural coil data provided in the input feed).
• Conservative Entry: —
• Breakout Level: —
• Extension: —
• ATR Context: Current ATR is 5.3% (High). This indicates elevated volatility, which is typical for biotech names in the pre-commercial or late-stage clinical phase.

2. The Thesis Layer

• Primary Secular Theme: Biotech & GLP-1 → Oncology (Tier Direct, High Confidence).
• Thesis Weighting: Immunome is a direct beneficiary of the secular shift toward targeted oncology therapies, specifically in the areas of desmoid tumors and fibroblast activation protein (FAP) targeting.
• Exposure Analysis: The company is not merely a passive participant but a primary developer of first-in-class assets. The thesis is reinforced by the successful completion of a pivotal Phase 3 trial (RINGSIDE) and the regulatory momentum of the NDA submission. The exposure is "Tier Direct" because the company's valuation is almost entirely dependent on the success of its lead asset, varegacestat, and the progression of its pipeline (IM-3050, IM-1617). There are no secondary secular themes listed in the membership data; the conviction rests entirely on the execution of the oncology pipeline.

3. The Business

Immunome, Inc. is a biopharmaceutical company focused on the discovery and advancement of antibody-based therapies and small molecules for cancer and infectious illnesses. As of June 2026, the company's business model relies on advancing its proprietary pipeline through clinical trials to generate regulatory approvals and subsequent commercialization rights or licensing deals.

Key Operational Milestones (as of 2026-06-13):

• Lead Asset (Varegacestat): The company submitted a New Drug Application (NDA) for varegacestat in April 2026, following positive topline results from the global pivotal Phase 3 RINGSIDE trial announced in December 2025. The trial demonstrated an 84% reduction in the risk of disease progression or death versus placebo (HR=0.16, p<0.0001) in patients with progressing desmoid tumors. Management expects to submit a Marketing Authorization Application (MAA) to the EMA by the end of 2026.
• Pipeline Progression:
• IM-3050: A FAP-targeted radioligand therapy (RLT) initiated its first Phase 1 site in March 2026 for FAP-expressing solid tumors.
• IM-1617: A first-in-class Antibody-Drug Conjugate (ADC) received IND clearance in April 2026, with a Phase 1 trial planned for Q2 2026.
• IM-1340: IND-enabling work is ongoing, with an IND submission expected in mid-2026.
• IM-1021: Observed objective responses in B-cell lymphoma were reported in November 2025, with initial data sharing planned for 2026.
• Financial Runway: According to the March 31, 2026, 10-Q filing, the company expects its existing cash and cash equivalents to fund current and planned operating expenses and capital expenditures for at least 12 months from the filing date.
• Other Assets: The company maintains a portfolio including IMM-BCP-01 (SARS-CoV-2 antibody cocktail) and IMM-ONC-01 (IL-38 immune checkpoint inhibitor), though the primary business focus remains on the oncology assets described above.

4. Archetype and Conviction

• Archetype: Growth Leader / Pre-Commercial Catalyst.
• The company fits the "Growth Leader" archetype in the context of a biotech pipeline, specifically one transitioning from late-stage clinical data to regulatory submission. It is not a "deep value" play (negative EPS consensus) nor a "cyclical recovery." It is a binary-event driven growth story where the "inflection" is the FDA approval of varegacestat.
• Valuation Context: The financial spine indicates forward consensus EPS of -2.14 for FY1 and -2.13 for FY2. This confirms the company is pre-revenue/pre-profit, with valuation driven entirely by the probability of regulatory success and future cash flow potential.
• Conviction Stack:
• Thesis Strength: High. The RINGSIDE trial data (HR=0.16) is statistically robust and addresses a significant unmet need (desmoid tumors).
• Evidence Quality: High. Multiple primary filings (E1, E7, E9, E10) corroborate the timeline and data.
• Structural Quality: N/A (No technical setup data).
• Setup Readiness: Low. The lack of a defined coil structure means the technical entry point is undefined.
• Rerating Potential: High, contingent on FDA approval. The market is currently pricing in the "form" of the NDA submission; a positive decision would likely trigger a significant re-rating.
• ATR Analysis: The current ATR of 5.3% (High) suggests the stock is sensitive to news flow. In the biotech sector, this volatility is expected around NDA submissions and trial readouts. It does not indicate a "severe loser" risk (which would be >8%) but does suggest wide price swings are likely.

5. Invalidation, Strengthening, and Gaps

• What Would Strengthen the Case:
• FDA approval of varegacestat (NDA acceptance leading to approval).
• Positive interim data from the IM-3050 Phase 1 trial.
• Extension of cash runway beyond the 12-month horizon or a strategic partnership/licensing deal announced.
• What Would Invalidate the Case:
• FDA Complete Response Letter (CRL) or rejection of the NDA for varegacestat.
• Failure to initiate the IM-3050 Phase 1 trial due to supply chain issues (radiotracer).
• Cash runway extending to less than 6 months without new capital.
• Gaps in Evidence:
• Commercialization Plan: No specific guidance on pricing, reimbursement strategy, or launch timeline for varegacestat is provided in the evidence.
• Dilution Risk: While cash runway is stated, there is no explicit mention of current share count or potential dilution from upcoming financing needs if the NDA is delayed.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Positive Phase 3 RINGSIDE data (HR=0.16) for varegacestat; NDA submitted April 2026; Cash runway sufficient for 12 months from March 2026. Key risks: FDA rejection or delay of NDA; failure to initiate IM-3050 Phase 1 due to radiotracer supply; cash burn rate exceeding runway if approval is delayed. Sizing hint: Position size should reflect binary regulatory risk; limit exposure to a small fraction of portfolio due to lack of technical setup confirmation. Expected path: Market will price in NDA approval probability; price likely to remain volatile until FDA decision; potential for significant rerating upon approval. Expected horizon: 6 to 12 months (time to FDA decision on NDA). Failure mode to watch: FDA issues a Complete Response Letter or requests additional data, delaying approval.